Venezuela, Cuba strengthen scientific ties - MPPRE

Venezuela, Cuba strengthen scientific ties

Last weekend, a Venezuelan delegation held a meeting in Cuba about the experience gained in research and innovation in the face of the COVID-19 pandemic.

The Minister of People’s Power for Science and Technology, Gabriela Jiménez, participated in this meeting to move forward with the multilateral cooperation with Cuba to face the COVID-19 challenges with the contributions made by science, technology and innovation in the region.

The issues tackled in the meeting included therapeutic care, epidemiological surveillance and monitoring of COVID-19 patients.

The Venezuelan delegation exchanged experiences with Cuban authorities Elba Rosa Pérez Montoya, minister of Science, Technology and Environment; Eduardo Martínez Díaz, president of Biocubafarma; and y José Ángel Portal Miranda, minister of Public Health.

The Venezuelan commission learned about the potential vaccines Cuba is currently developing: Soberana 01, Soberana 02, Mambisa and Abdala.

After the meeting, Minister Jiménez highlighted that the results of these vaccines are very promising. “We hope that, in the first half of the year, a Cuban vaccine be developed and ongoing promising results can be obtained.”

The Venezuelan science minister said that the Cuban Government is widely known for its scientific, technological development with a humanist vision based on the protection of the people; in this case, through the development of safe, effective vaccines to prevent SARS-CoV-2.

Jiménez explained that with four vaccine candidates, Cuba becomes the first Latin American country with developments in the field of prevention of SARS-CoV-2 infections and a member of the select group of 47 countries working on a vaccine against novel coronavirus.

The Venezuelan science minister reaffirmed Venezuela’s support for Cuban research on these biotechnological developments.

“We reaffirmed the will of the Scientific Council and the Presidential Commission for the Prevention and Control of COVID-19 to keep in permanent touch for cooperation and complementarity, and even to conduct phase 3 trials with these vaccines when appropriate,” said Jiménez.